Efficacy
DISEASE
Median PFS was 8.02 (95%CI 5.36–10.67) months (Table 
Clinical outcomesITT: intent-to-treat; PP: per-protocol; mPFS: median progression-free survival; mOS: median overall survival; CR: complete response; PR: partial response; SD: stable disease; ORR: objective response rate; DCR: disease control rate
(
(